曲美替尼联合GSK2141795治疗持续性或复发性宫颈癌的单臂单阶段II期试验结果
本研究为研究者发起的II期试验,评估MEK抑制剂曲美替尼联合AKT抑制剂GSK2141795在复发性宫颈癌中的疗效与安全性。计划入组35例,实际14例入组并接受至少一剂研究药物后因GSK2141795研发终止而提前结束。未观察到确认缓解,1例未确认部分缓解,8例疾病稳定;57%患者发生3/4级不良事件,50%需减量。联合方案可行但抗肿瘤活性极小,不支持进一步开发。
要点
- 曲美替尼联合GSK2141795在复发性宫颈癌中未观察到确认缓解。
- 57%患者发生3/4级不良事件,50%患者需减量。
- 研究因GSK2141795研发终止提前结束,14例患者数据不支持进一步开发该联合方案。
核心结论
- 曲美替尼联合GSK2141795可行但需因不良事件暂停给药和调整剂量;抗肿瘤活性极小,即使在PI3K或RAS通路改变的患者中亦如此。
- 研究因GSK2141795研发停止而提前终止,14例患者的结果不支持该联合方案在宫颈癌中进一步开发。
研究设计与样本
- 研究者发起的II期单臂单阶段研究,联合MEK抑制剂曲美替尼与AKT抑制剂GSK2141795治疗复发性宫颈癌。
- 计划入组35例,实际14例入组并接受至少一剂研究药物。
- 主要终点为最佳肿瘤缓解;次要终点包括无进展生存、总生存和安全性评估;转化目标包括PI3K和RAS信号通路基因分子改变特征分析。
主要发现
- 无确认缓解;1例未确认部分缓解,8例疾病稳定,3例最佳缓解为进展,2例不可评估。
- 毒性多为1级和2级,但57%患者经历3/4级不良事件,50%患者需要减量。
局限性
- 研究因GSK2141795研发停止而提前终止,计划入组35例但仅14例入组并接受至少一剂研究药物。
- 作者结论指出14例患者的结果不支持该联合方案进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improved treatment for advanced cervical cancer is needed; currently, treatment options include combined chemotherapy and bevacizumab or pembrolizumab monotherapy for PD-L1 positive disease. PIK3CA and KRAS mutations have been reported in cervical cancers; this study therefore tested dual inhibition of PI3K and RAS signaling by combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 in recurrent cervical cancer. METHODS: This was an investigator-initiated phase II study combining trametinib and GSK2141795 in patients with recurrent cervical cancer. Primary endpoint was best tumor response; secondary endpoints included progression free survival, overall survival, and safety assessment. Translational objectives included characterization of molecular alterations in PI3K and RAS signaling pathway genes. RESULTS: Planned accrual was 35 patients; 14 patients were enrolled and received at least one dose of study drug before the study was terminated due to discontinuation of GSK2141795 development. There were no confirmed responses; 1 patient had an unconfirmed PR, 8 had stable disease, 3 had progression as best response, and 2 were unevaluable. Toxicities were mostly grade 1 and 2, although 57% of patients experienced grade 3/4 adverse events and 50% patients required a dose reduction. CONCLUSIONS: The combination of trametinib and GSK2141795 was feasible but required dose holds and modifications for adverse events; however, anti-cancer activity was minimal, even in patients with PI3K or RAS pathway alterations. Although the study was terminated early after GSK2141795 development was halted, the findings in these 14 patients do not support further development of this combination in cervical cancer.
引用
- Liu JF, Gray KP, Wright AA, et al. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019. PMID: 31118140. doi:10.1016/j.ygyno.2019.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。